These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 35443802)

  • 41. Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial.
    Song Y; Zhou H; Zhang H; Liu W; Shuang Y; Zhou K; Lv F; Xu H; Zhou J; Li W; Wang H; Zhang H; Huang H; Zhang Q; Xu W; Ge Z; Xiang Y; Wang S; Gao D; Yang S; Lin J; Wang L; Zou L; Zheng M; Liu J; Shao Z; Pang Y; Xia R; Chen Z; Hou M; Yao H; Feng R; Cai Z; Zhang M; Ran W; Liu L; Zeng S; Yang W; Liu P; Liang A; Zuo X; Zou Q; Ma J; Sang W; Guo Y; Zhang W; Cao Y; Li Y; Feng J; Du X; Zhang X; Zhao H; Zhou H; Yu J; Sun X; Zhu J; Qiu L
    Adv Ther; 2021 Apr; 38(4):1889-1903. PubMed ID: 33751401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients.
    Qin Y; He X; Chen X; Xie Z; Yang J; Yang S; Liu P; Zhou S; Zhang C; Gui L; Shi Y
    Eur J Haematol; 2023 Sep; 111(3):356-364. PubMed ID: 37294015
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
    Goy A; Ramchandren R; Ghosh N; Munoz J; Morgan DS; Dang NH; Knapp M; Delioukina M; Kingsley E; Ping J; Beaupre DM; Neuenburg JK; Ruan J
    Blood; 2019 Sep; 134(13):1024-1036. PubMed ID: 31331917
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of USP1 reverses the chemotherapy resistance through destabilization of MAX in the relapsed/refractory B-cell lymphoma.
    Li XY; Wu JC; Liu P; Li ZJ; Wang Y; Chen BY; Hu CL; Fei MY; Yu PC; Jiang YL; Xu CH; Chang BH; Chen XC; Zong LJ; Zhang JY; Fang Y; Sun XJ; Xue K; Wang L; Chen SB; Jiang SY; Gui AL; Yang L; Gu JJ; Yu BH; Zhang QL; Wang L
    Leukemia; 2023 Jan; 37(1):164-177. PubMed ID: 36352191
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
    Advani R; Flinn I; Popplewell L; Forero A; Bartlett NL; Ghosh N; Kline J; Roschewski M; LaCasce A; Collins GP; Tran T; Lynn J; Chen JY; Volkmer JP; Agoram B; Huang J; Majeti R; Weissman IL; Takimoto CH; Chao MP; Smith SM
    N Engl J Med; 2018 Nov; 379(18):1711-1721. PubMed ID: 30380386
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD19(+) CD20(-) CD27(hi) IL-s10-producing B cells are overrepresented in R-CHOP-treated DLBCL patients in complete remission.
    Qiu H; Li J; Feng Z; Yuan J; Lu J; Hu X; Gao L; Lv S; Yang J; Chen L
    Clin Exp Pharmacol Physiol; 2016 Sep; 43(9):795-801. PubMed ID: 27247195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
    Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study.
    Wu J; Song Y; Su L; Xu L; Chen T; Zhao Z; Zhang M; Li W; Hu Y; Zhang X; Gao Y; Niu Z; Feng R; Wang W; Peng J; Li X; Ouyang X; Wu C; Zhang W; Zeng Y; Xiao Z; Liang Y; Zhuang Y; Wang J; Sun Z; Bai H; Cui T; Feng J
    BMC Cancer; 2016 Jul; 16():537. PubMed ID: 27460571
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma.
    Sparano JA; Lee JY; Kaplan LD; Ramos JC; Ambinder RF; Wachsman W; Aboulafia D; Noy A; Henry DH; Ratner L; Cesarman E; Chadburn A; Mitsuyasu R
    Haematologica; 2021 Mar; 106(3):730-735. PubMed ID: 32107337
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.
    Arcari A; Chiappella A; Spina M; Zanlari L; Bernuzzi P; Valenti V; Tani M; Marasca R; Cabras MG; Zambello R; Santagostino A; Ilariucci F; Carli G; Musto P; Savini P; Marino D; Ghio F; Gentile M; Cox MC; Vallisa D
    Leuk Lymphoma; 2016 Aug; 57(8):1823-30. PubMed ID: 26666433
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
    Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in Immunotherapy for Diffuse Large B Cell Lymphoma.
    Shouse G; Herrera AF
    BioDrugs; 2021 Sep; 35(5):517-528. PubMed ID: 34264504
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution.
    Li YJ; Li ZM; Rao HL; Xia Y; Huang HQ; Xia ZJ; Li S; Li WY; Jiang WQ
    J Transl Med; 2012 May; 10():84. PubMed ID: 22554077
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Ivanov V; Coso D; Chetaille B; Esterni B; Olive D; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Broussais-Guillaumot F; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2014 Nov; 55(11):2508-13. PubMed ID: 24506467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
    Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
    Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.